Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
C4 Therapeutics Analyst Ratings and Price Targets | NASDAQ:CCCC | Benzinga
C4 Therapeutics Inc has a consensus price target of $9.22 based on the ratings of 9 analysts. The high is $20 issued by BMO Capital on August 6, 2024. The low is $2 issued by B of A Securities on October 9, 2023. The 3 most-recent analyst ratings were released by Wells Fargo, Stephens & Co., and BMO Capital on December 19, 2024, November 18, 2024, and August 6, 2024, respectively. With an average price target of $12 between Wells Fargo, Stephens & Co., and BMO Capital, there's an implied 742.11% upside for C4 Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wells Fargo
Stephens & Co.
BMO Capital
Stifel
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for C4 Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 12/19/2024 | Buy Now | 742.11% | Wells Fargo | Derek Archila62% | $8 → $12 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 11/18/2024 | Buy Now | 180.7% | Stephens & Co. | Sudan Loganathan41% | → $4 | Initiates | → Equal-Weight | Get Alert |
| 08/06/2024 | Buy Now | 1303.51% | BMO Capital | Etzer Darout48% | $20 → $20 | Reiterates | Outperform → Outperform | Get Alert |
| 05/09/2024 | Buy Now | 461.4% | Wells Fargo | Derek Archila62% | $7 → $8 | Maintains | Equal-Weight | Get Alert |
| 05/09/2024 | Buy Now | 882.46% | Stifel | Bradley Canino40% | $13 → $14 | Maintains | Buy | Get Alert |
| 02/26/2024 | Buy Now | 461.4% | Morgan Stanley | Terence Flynn65% | $1 → $8 | Maintains | Equal-Weight | Get Alert |
| 02/23/2024 | Buy Now | 812.28% | Stifel | Bradley Canino40% | $12 → $13 | Reiterates | Buy → Buy | Get Alert |
| 01/29/2024 | Buy Now | 321.05% | JP Morgan | Eric Joseph43% | → $6 | Upgrade | Underweight → Neutral | Get Alert |
| 12/13/2023 | Buy Now | 742.11% | Stifel | Bradley Canino40% | $2 → $12 | Upgrade | Hold → Buy | Get Alert |
| 11/06/2023 | Buy Now | -29.82% | Morgan Stanley | Terence Flynn65% | $3 → $1 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 11/03/2023 | Buy Now | 1022.81% | BMO Capital | Etzer Darout48% | $18 → $16 | Maintains | Outperform | Get Alert |
| 11/02/2023 | Buy Now | 391.23% | HC Wainwright & Co. | Andrew Fein61% | $17 → $7 | Maintains | Buy | Get Alert |
| 10/09/2023 | Buy Now | 40.35% | B of A Securities | Chi Fong25% | $5 → $2 | Maintains | Neutral | Get Alert |
| 08/09/2023 | Buy Now | 1092.98% | HC Wainwright & Co. | Andrew Fein61% | $25 → $17 | Maintains | Buy | Get Alert |
| 05/30/2023 | Buy Now | 601.75% | Evercore ISI Group | Gavin Clark-Gartner38% | $20 → $10 | Maintains | Outperform | Get Alert |
| 05/12/2023 | Buy Now | 110.53% | Morgan Stanley | Terence Flynn65% | $5 → $3 | Maintains | Underweight | Get Alert |
| 05/08/2023 | Buy Now | 1654.39% | HC Wainwright & Co. | Andrew Fein61% | $35 → $25 | Maintains | Buy | Get Alert |
| 03/28/2023 | Buy Now | 250.88% | B of A Securities | Chi Fong25% | $11 → $5 | Maintains | Neutral | Get Alert |
| 02/27/2023 | Buy Now | 250.88% | Morgan Stanley | Terence Flynn65% | $6 → $5 | Maintains | Underweight | Get Alert |
| 02/24/2023 | Buy Now | 2356.14% | HC Wainwright & Co. | Andrew Fein61% | → $35 | Reiterates | → Buy | Get Alert |
| 02/24/2023 | Buy Now | 250.88% | JP Morgan | Eric Joseph43% | $15 → $5 | Downgrade | Neutral → Underweight | Get Alert |
| 01/03/2023 | Buy Now | 531.58% | Wells Fargo | Derek Archila62% | $11 → $9 | Maintains | Equal-Weight | Get Alert |
| 11/08/2022 | Buy Now | 671.93% | Wells Fargo | Derek Archila62% | $12 → $11 | Maintains | Equal-Weight | Get Alert |
| 11/04/2022 | Buy Now | 952.63% | JP Morgan | Eric Joseph43% | $22 → $15 | Downgrade | Overweight → Neutral | Get Alert |
| 10/11/2022 | Buy Now | 321.05% | Morgan Stanley | Terence Flynn65% | → $6 | Initiates | → Underweight | Get Alert |
FAQ
What is the target price for C4 Therapeutics (CCCC) stock?
The latest price target for C4 Therapeutics (NASDAQ:CCCC) was reported by Wells Fargo on December 19, 2024. The analyst firm set a price target for $12.00 expecting CCCC to rise to within 12 months (a possible 742.11% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for C4 Therapeutics (CCCC)?
The latest analyst rating for C4 Therapeutics (NASDAQ:CCCC) was provided by Wells Fargo, and C4 Therapeutics upgraded their overweight rating.
When was the last upgrade for C4 Therapeutics (CCCC)?
The last upgrade for C4 Therapeutics Inc happened on December 19, 2024 when Wells Fargo raised their price target to $12. Wells Fargo previously had an equal-weight for C4 Therapeutics Inc.
When was the last downgrade for C4 Therapeutics (CCCC)?
The last downgrade for C4 Therapeutics Inc happened on February 24, 2023 when JP Morgan changed their price target from $15 to $5 for C4 Therapeutics Inc.
When is the next analyst rating going to be posted or updated for C4 Therapeutics (CCCC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of C4 Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for C4 Therapeutics was filed on December 19, 2024 so you should expect the next rating to be made available sometime around December 19, 2025.
Is the Analyst Rating C4 Therapeutics (CCCC) correct?
While ratings are subjective and will change, the latest C4 Therapeutics (CCCC) rating was a upgraded with a price target of $8.00 to $12.00. The current price C4 Therapeutics (CCCC) is trading at is $1.43, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
